1
|
Rafii H, Garnier F, Ruggeri A, Ionescu I, Ballot C, Bensoussan D, Chabannon C, Dazey B, De Vos J, Gautier E, Giraud C, Larghero J, Cras A, Mialou V, Persoons V, Pouthier F, Thibert JB, Dalle JH, Michel G, Kenzey C, Volt F, Rocha V, Bay JO, Rubio MT, Faucher C, Marry E, Gluckman E. Umbilical cord blood transplants facilitated by the French cord blood banks network. On behalf of the Agency of Biomedicine, Eurocord and the French society of bone marrow transplant and cell therapy (SFGM-TC). Bone Marrow Transplant 2021; 56:2497-2509. [PMID: 33990703 PMCID: PMC8120495 DOI: 10.1038/s41409-021-01313-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2020] [Revised: 03/04/2021] [Accepted: 04/13/2021] [Indexed: 11/18/2022]
Abstract
The public French Cord Blood Banks Network was established in 1999 with the objective of standardizing the practices governing umbilical cord blood (UCB) banking in France. The Network adopted a strategy to optimize its inventory and improve the quality of its banked units based on a quality improvement process using outcome data regularly provided by Eurocord. This study aimed to describe the results, over 10 years, of UCBT facilitated by a national network that used the same criteria of UCB collection and banking and to assess how modifications of banking criteria and unit selection might influence transplant outcomes. Nine hundred and ninety-nine units (593 single-unit and 203 double-unit grafts) were released by the Network to transplant 796 patients with malignant (83%) and non-malignant (17%) diseases. Median cell dose exceeded 3.5 × 107 TNC/kg in 86%. There was a trend to select units more recently collected and with higher cell dose. Neutrophil engraftment was 88.2% (85.7-90.7) and 79.3% (72.6-86.5) respectively for malignant and non-malignant diseases with a trend to faster recovery with higher cell doses. The respective 3-year transplant-related mortality were 31.1% (27.5-35.1) and 34.3% (27.0-43.5). OS was 49% ± 4 in malignant and 62% ± 4 in non-malignant disorders. In multivariate analysis, cell dose was the only unit-related factor associated with outcomes. Our results reflect the benefit on clinical outcomes of the strategy adopted by the Network to bank units with higher cell counts.
Collapse
Affiliation(s)
- Hanadi Rafii
- Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France.
- Monacord, Centre Scientifique de Monaco, Monaco, Monaco.
| | | | - Annalisa Ruggeri
- Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France
- Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Irina Ionescu
- Agency of Biomedecine, Saint Denis La Plaine, France
| | - Caroline Ballot
- Cell Therapy unit, Etablissement Français du Sang Hauts de France Normandie, site de LILLE - Belfort, Lille, France
| | - Danièle Bensoussan
- Tissue Engineering and Cell Therapy unit, Regional University hospital, Nancy, France
| | - Christian Chabannon
- Paoli-Calmettes Institute, Departement of Cancer Biology, Inserm CBT1409, Marseille, France
| | - Bernard Dazey
- Cell Therapy unit, Etablissement Français du Sang, Bordeaux, France
| | - John De Vos
- Cell Therapy unit, University hospital, Montpellier, France
| | - Eric Gautier
- Cell Therapy unit, Etablissement Français du Sang, Créteil, France
| | - Christine Giraud
- Department of Hematology and Cell Therapy, Etablissement Français du Sang, University hospital, Poitiers, France
| | - Jérome Larghero
- Cell Therapy Unit and Cord Blood Bank, AP-HP, Hôpital Saint Louis, Paris, France
| | - Audrey Cras
- Cell Therapy Unit and Cord Blood Bank, AP-HP, Hôpital Saint Louis, Paris, France
| | - Valérie Mialou
- Cell Therapy unit, Etablissement Français du Sang, hopital E. Herriot, Lyon, France
| | - Virginie Persoons
- Cell Therapy and Tissue Engineering unit, Etablissement Français du Sang, Grenoble, France
| | - Fabienne Pouthier
- Cell and Tissue Engineering unit, Etablissement Francais du Sang, Besançon, France
| | | | - Jean-Hugues Dalle
- Hopital Robert Debré, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Gerard Michel
- Aix-Marseille University and La Timone Children's Hospital, Marseille, France
| | - Chantal Kenzey
- Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France
- Monacord, Centre Scientifique de Monaco, Monaco, Monaco
| | - Fernanda Volt
- Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France
- Monacord, Centre Scientifique de Monaco, Monaco, Monaco
| | - Vanderson Rocha
- Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France
- Department of Hematology, Clinics Hospital, University of São Paulo Medical School, São Paulo, Brazil
| | - Jacques-Olivier Bay
- Department of Hematology and Stem Cell Transplantation, Clermont University, Clermont-Ferrand, France
| | - Marie-Thérèse Rubio
- Department of Hematology and Stem Cell Transplantation, regional university hospital, Nancy, France
| | | | - Evelyne Marry
- Agency of Biomedecine, Saint Denis La Plaine, France
| | - Eliane Gluckman
- Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France
- Monacord, Centre Scientifique de Monaco, Monaco, Monaco
| |
Collapse
|
2
|
A cost analysis of public cord blood banks belonging to the Italian Cord Blood Network. BLOOD TRANSFUSION = TRASFUSIONE DEL SANGUE 2017; 16:313-320. [PMID: 28488969 DOI: 10.2450/2017.0251-16] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Accepted: 12/02/2016] [Indexed: 11/21/2022]
Abstract
BACKGROUND Public cord blood banking is currently managed in Italy by a network of 19 regional cord blood banks coordinated by the National Blood Centre and the National Transplant Centre. A cost analysis was carried out within the Italian network to determine the relationship between cost of cord blood collection and banking and size of the bank inventory, which ranged from 106 to 9,341 units on December 31st, 2012. MATERIALS AND METHODS The 19 banks were invited to report costs incurred in 2012 related to cord blood unit collection, transportation, biological validation, characterisation, manipulation, cryopreservation, storage, data management, and general costs. Missing information on selected items was replaced with standardised costs represented by average data obtained from the reporting banks. Eight banks (52%) participated in the study. Average costs were determined in the three banks with inventories of >3,000 units vs the three banks with inventories of <1,000 units. RESULTS Both cord blood collection and cord blood banking costs per unit were lower in the larger banks than in the smaller banks (average collection costs: € 119.25 and € 151.31, respectively; average banking costs: € 3,614.15 and € 8,158.37, respectively). DISCUSSION The study outlined an inverse relationship between the costs of cord blood collection and banking and the size of the bank inventory, suggesting that scale economies could be obtained through centralisation of banking activities.
Collapse
|